Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Gains from Investment Securities over the past 11 years, most recently at -$693000.0 for Q4 2025.

  • Quarterly Gains from Investment Securities rose 42.35% to -$693000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.0 million for FY2025, 0.0% changed from the prior year.
  • Gains from Investment Securities was -$693000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $1.6 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $4.6 million in Q3 2023 and troughed at -$4.3 million in Q2 2023.
  • The 5-year median for Gains from Investment Securities is $266500.0 (2022), against an average of $530450.0.
  • The largest YoY upside for Gains from Investment Securities was 1996.67% in 2023 against a maximum downside of 322.44% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$722000.0 in 2021, then soared by 131.16% to $225000.0 in 2022, then skyrocketed by 1428.0% to $3.4 million in 2023, then plummeted by 134.96% to -$1.2 million in 2024, then soared by 42.35% to -$693000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gains from Investment Securities are -$693000.0 (Q4 2025), $1.6 million (Q3 2025), and $308000.0 (Q2 2025).